AstraZeneca has terminated the development of two Alexion-acquired assets - vemircopan for rare liver and kidney conditions and ALXN1910 for bone metabolism disorders - due to insufficient efficacy data.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.